18AntiviralPK – Presentation

Wednesday 14 June 2017

  Session 1: Approaches to Treating CMV and Influenza 
  Current and Future Treatment of CMV
Robin Avery, MD - Johns Hopkins University, USA
Download presentation
 O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers
Dr Thomas Kakuda
Download presentation
 
  Session 2: The Complexity of DDIs Involving PK Enhancement 
 O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?
Dr Dario Cattaneo
Download presentation
 O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients
Dr Jose Molto
Download presentation
 O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins
Dr Joseph Custodio
Download presentation
 O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives
Dr Sophia Majeed
Download presentation
 O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir
Dr Catia Marzolini
Download presentation
  

Thursday 15 June 2017

  Session 3: Challenges and Approaches to Treatment in Special Patient Populations 
  Current Challenges in Pediatric Drug Development 
Robert Ward, MD, FAAP, FCP - University of Utah, USA
Download presentation
  Clinical Aspects of Pediatric Treatment
Tim Cressey, PhD - Chiang Mai University, Thailand
Download presentation
 O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum
Dr Pauline Bollen
Download presentation
 O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.
Dr Marta Boffito
Download presentation
 
  Session 4: Hepatitis B Virus 
  HBV therapy & Approaches to Cure
Jordan Feld, MD, MPH - Toronto Western Hospital Liver Center, Canada
Download presentation
 
  Session 5: Exploration of Less-drug Regimens 
  
 O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis
Dr Kimberly Adkison
Download presentation
 O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
Dr Sandrine Lefeuvre
Download presentation
 
  Session 6: Implications of Drug Transport and Metabolism in Drug Development 
  Transporter mediated DDI
Kathy Giacomini, PhD - University of California, San Francisco, USA
Presentation not available
  FDA perspective
Kellie Reynolds, PharmD - U.S. Food & Drug Administration, USA
Download presentation
 O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015
Dr Tyler Shugg
Download presentation
 O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp
Dr. Brian Kirby 
Download presentation
 
  Session 7: Clinical Cases 
Clinical Case Discussions
  Challenges in managing the aging HIV-infected patient
Babafemi Taiwo, MBBS - Northwestern University, USA
Presentation not (yet) available
  DDI’s in Aging HIV infected Patients
Alice Pau, PharmD - National Institutes of Health, USA
Download presentation
  DDI’s in Aging HCV infected Patients
Elise Smolders, MSc - Radboudumc Nijmegen, The Netherlands
Download presentation

Friday 16 June 2017

  Session 8: Long Acting Antivirals: Advanced drug delivery 
  Long Acting Antivirals: Advanced drug delivery
Mark Milad, PharmD - Bill & Melinda Gates Foundation, USA
Download presentation
 O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence
Dr Nathan Hanan
Download presentation
 O_15: Identification of long-acting NRTI candidates through in silico modelling
Dr Marco Siccardi
Download presentation
 O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration
Dr Steven Sanche
Download presentation
 O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects
Dr Mark Johnson
Download presentation
 
  Session 9: Hepatitis C Virus 
 O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilate
Dr Matthew Kosloski
Download presentation
 O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme.
Dr Omar Elsherif
Download presentation
 O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Dr. Kimberly Garrison
Download presentation
 O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin
Dr Su-young Choi
Download presentation
Debate: Do we need more HCV Drugs?
  Pro Standpoint
Nancy Reau, MD - Rush University Medical Center, USA
Download presentation
  Con Standpoint
Jürgen Rockstroh, MD - University of Bonn, Germany
Download presentation
 
  Session 10: Challenges in Drug Development for Other Viruses Than HIV or Hepatitis 
  Merck: CMV 
Cyrus Badshah, MD, PhD  - Merck, USA
Download presentation
  Janssen: Influenza
Thomas Kakuda, PharmD - Janssen/Alios, USA
Download presentation
  Gilead: RSV 
Erik Mogalian - Gilead, USA
Download presentation